Cameka Campbell
Family · Orange City, FLNPI 1043753437
Payments from drug & device makers
Across 227 payments — averaging $26.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- AstraZeneca$1K
- Indivior Inc.$538
- GSK$424
- Novo Nordisk$370
- Teva Pharmaceuticals USA, Inc.$261
- plus $1K from 19 others
What the payments were for
- Food & beverage$5,994100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 61 | $1,706 |
| AstraZeneca | 35 | $1,358 |
| Indivior Inc. | 39 | $538 |
| GSK | 18 | $424 |
| Novo Nordisk | 15 | $370 |
| Teva Pharmaceuticals USA, Inc. | 3 | $261 |
| Braeburn Inc. | 12 | $237 |
| Acadia Pharmaceuticals Inc | 3 | $177 |
| Eisai Inc. | 2 | $135 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $126 |
| Pfizer | 6 | $99 |
| Medtronic | 7 | $98 |
| Lilly USA, LLC | 5 | $86 |
| Scilex Pharmaceuticals Inc. | 4 | $65 |
| Exact Sciences | 3 | $56 |
| Bayer | 2 | $45 |
| Pear Therapeutics (US), Inc. | 2 | $39 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $39 |
| Xeris Pharmaceuticals, Inc. | 1 | $25 |
| Axonics, Inc. | 1 | $22 |
| Johnson & Johnson | 1 | $21 |
| Abbott | 1 | $21 |
| Amgen | 1 | $20 |
| IBSA Pharma Inc. | 1 | $13 |
| Esperion Therapeutics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,994 in reported general payments places this provider in the 90th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 125 | $21,486 |
| Buprenorphine Hcl | 13 | $845 |
| Neomycin-Polymyxin-HcNeomycin/Polymyxin B/Hydrocort | 11 | $663 |
| Methylprednisolone | 91 | $636 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 28 | $320 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 11 | $309 |
| Prednisone | 72 | $118 |
| Azithromycin | 15 | $76 |
| Amoxicillin | 23 | $64 |
| Doxycycline Hyclate | 12 | $56 |
| Cephalexin | 14 | $40 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 11 | $36 |
Paid to pharmacies, not to this prescriber.
Other family in Orange City
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.